ArticleFrontiers in neurology2025
Optical coherence tomography angiography in patients with focal epilepsy.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07716930 (Retina-Based Biomarkers in Epilepsy), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Retina-Based Biomarkers in Epilepsy: Structural and Microvascular OCT Changes and Inflammatory Markers (sCD14, sCD163, CCL2, IL-1β) in Relation to Pathophysiology, Phenotype, Prognosis, and Drug-Resistant Epilepsy (DRE)
Who cites it
1 citing paper in PubMed.
- Resveratrol's Neuroprotective Effects on the Retina in a Pentylenetetrazol-Induced Epilepsy Model in Rats: Insights into SIRT1 Signaling, Apoptosis, and Gliosis.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to compare optical coherence tomography angiography (OCTA) data in individuals with focal epilepsy and healthy individuals and to investigate the effect of antiseizure medications (ASM) on OCTA data. Methods: We examined 48 consecutive patients with focal epilepsy and 46 healthy controls. Area and skeleton density of superficial and deep capillary plexuses in the macular area and peripapillary radial capillary plexus were measured. Results: In general, no differences in OCTA parameters were found between groups of individuals with epilepsy and healthy individuals. A comparison of individuals with epilepsy with and without comorbid major depressive disorder revealed no differences in OCTA data. However, the area and skeleton densities of the perfused capillary retinal vascular bed in the macular region showed a negative association with the use of valproates and modifiers of the presynaptic release machinery, whereas only the skeleton density of the deep capillary plexus showed a positive association with the use of modulators of voltage-gated sodium channels. Conclusion: OCTA revealed different effects of various ASM groups on the perfused macular capillary bed. These findings suggest that OCTA parameters could serve as potential biomarkers for assessing ASM effects on small vessels and capillaries in the brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.